

## difelikefalin (Kapruvia®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2623	treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.  SMC restriction: for use in patients with an inadequate response to best supportive care for reducing itch.	Not routinely available as there is a local preference for alternative medicines	28/02/2024	28/02/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8108/difelikefalin-kapruvia-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8108/difelikefalin-kapruvia-final-jan-2024-for-website.pdf</a>				

## ravulizumab (Ultomiris®)

SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2657	As an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.	Not routinely available as not recommended for use in NHS Scotland	28/02/2024	28/02/2024
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8104/ravulizumab-ultomiris-gmg-non-sub-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8104/ravulizumab-ultomiris-gmg-non-sub-final-jan-2024-for-website.pdf</a>				

<b>cabozantinib (Cabometyx®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2590	as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.	Not routinely available as not recommended for use in NHS Scotland	28/02/2024	28/02/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8107/cabozantinib-cabometyx-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8107/cabozantinib-cabometyx-final-jan-2024-for-website.pdf</a>				
<b>secukinumab (Cosentyx®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2592	for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.	Available in line with local or regional guidance	28/02/2024	28/02/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8106/secukinumab-cosentyx-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8106/secukinumab-cosentyx-final-jan-2024-for-website.pdf</a>				

<b>dupilumab (Dupixent®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2598	for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.	Available in line with local or regional guidance	28/02/2024	28/02/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8109/dupilumab-dupixent-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8109/dupilumab-dupixent-final-jan-2024-for-website.pdf</a>				
<b>loncastuximab tesirine (Zynlonta®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date of ADTC</b>	<b>Date of decision / Expected date of decision</b>
SMC2609	as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.  SMC restriction: where chimeric antigen receptor (CAR) T-cell therapy is unsuitable, not tolerated or ineffective.	Available in line with local or regional guidance	28/02/2024	28/02/2024
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8110/loncastuximab-tesirine-zynlonta-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8110/loncastuximab-tesirine-zynlonta-final-jan-2024-for-website.pdf</a>				

ravulizumab (Ultomiris®)				
SMC Drug ID	Conditions	Decision	Date of ADTC	Date of decision / Expected date of decision
SMC2658	Treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive.	Not routinely available as not recommended for use in NHS Scotland	28/02/2024	28/02/2024
<b>Other Decision Specified :</b> Non-submission				
<b>Web Link :</b> <a href="https://www.scottishmedicines.org.uk/media/8105/ravulizumab-ultomiris-nmosd-non-sub-final-jan-2024-for-website.pdf">https://www.scottishmedicines.org.uk/media/8105/ravulizumab-ultomiris-nmosd-non-sub-final-jan-2024-for-website.pdf</a>				